StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3018% below fair value
$4.34−0.22 (-4.82%)

Close on Nov 18, 2026Market cap $483.95MP/E –Yield –

Gyre Therapeutics cash

Cash and short-term investments held at the end of each period.

Gyre Therapeutics's cash was $57.42M at Sep 30, 2026. For fiscal 2025 it was $64.55M, up 142.0% from the year before. Over ten years it grew 7.1% a year on average. The highest annual figure on record is $214.02M in fiscal 2010.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$64.55M+142.0%
FY2024Dec 31, 2024$26.67M-20.4%
FY2023Dec 31, 2023$33.50M+54.4%
FY2022Dec 31, 2022$21.70M-53.7%
FY2021Dec 31, 2021$46.90M-42.7%
FY2020Dec 31, 2020$81.90M+6.5%
FY2019Dec 31, 2019$76.90M-36.0%
FY2018Dec 31, 2018$120.10M+270.7%
FY2017Dec 31, 2017$32.40M+89.5%
FY2016Dec 31, 2016$17.10M-47.4%
FY2015Dec 31, 2015$32.50M-38.1%
FY2014Dec 31, 2014$52.50M+29.1%
FY2013Dec 31, 2013$40.67M-11.8%
FY2012Dec 31, 2012$46.12M-76.3%
FY2011Dec 31, 2011$195.00M-8.9%
FY2010Dec 31, 2010$214.02M+155.1%
FY2009Dec 31, 2009$83.91M+63.9%
FY2008Dec 31, 2008$51.20M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$57.42M-4.4%
Q2 FY2026Jun 30, 2026$57.35M+5.5%
Q1 FY2026Mar 31, 2026$49.81M+66.6%
Q4 FY2025Dec 31, 2025$64.55M+142.0%
Q3 FY2025Sep 30, 2025$60.05M+139.3%
Q2 FY2025Jun 30, 2025$54.37M+116.6%
Q1 FY2025Mar 31, 2025$29.89M-20.0%
Q4 FY2024Dec 31, 2024$26.67M-20.4%
Q3 FY2024Sep 30, 2024$25.09M+1026.2%
Q2 FY2024Jun 30, 2024$25.10M+262.6%
Q1 FY2024Mar 31, 2024$37.35M+361.2%
Q4 FY2023Dec 31, 2023$33.50M+54.4%
Q3 FY2023Sep 30, 2023$2.23M-90.4%
Q2 FY2023Jun 30, 2023$6.92M-90.8%
Q1 FY2023Mar 31, 2023$8.10M-76.7%
Q4 FY2022Dec 31, 2022$21.70M-53.7%
Q3 FY2022Sep 30, 2022$23.09M-64.2%
Q2 FY2022Jun 30, 2022$75.39M-12.8%
Q1 FY2022Mar 31, 2022$34.82M-67.5%
Q4 FY2021Dec 31, 2021$46.90M-42.7%
Q3 FY2021Sep 30, 2021$64.50M-38.0%
Q2 FY2021Jun 30, 2021$86.50M-26.3%
Q1 FY2021Mar 31, 2021$107.00M+2.4%
Q4 FY2020Dec 31, 2020$81.90M+6.5%
Q3 FY2020Sep 30, 2020$104.10M+22.5%
Q2 FY2020Jun 30, 2020$117.40M+24.9%
Q1 FY2020Mar 31, 2020$104.50M-0.8%
Q4 FY2019Dec 31, 2019$76.90M-36.0%
Q3 FY2019Sep 30, 2019$85.00M-34.2%
Q2 FY2019Jun 30, 2019$94.00M-31.0%
Q1 FY2019Mar 31, 2019$105.30M-26.6%
Q4 FY2018Dec 31, 2018$120.10M+270.7%
Q3 FY2018Sep 30, 2018$129.22M+370.8%
Q2 FY2018Jun 30, 2018$136.15M+320.4%
Q1 FY2018Mar 31, 2018$143.52M+887.5%
Q4 FY2017Dec 31, 2017$32.40M+89.5%
Q3 FY2017Sep 30, 2017$27.45M–
Q2 FY2017Jun 30, 2017$32.39M–
Q1 FY2017Mar 31, 2017$14.53M–
Q4 FY2016Dec 31, 2016$17.10M–

More Gyre Therapeutics figures

See a number that looks wrong?